NO20026000D0 - Behandling og forebyggelse av hjertelidelser forbundet med insulinresistens - Google Patents

Behandling og forebyggelse av hjertelidelser forbundet med insulinresistens

Info

Publication number
NO20026000D0
NO20026000D0 NO20026000A NO20026000A NO20026000D0 NO 20026000 D0 NO20026000 D0 NO 20026000D0 NO 20026000 A NO20026000 A NO 20026000A NO 20026000 A NO20026000 A NO 20026000A NO 20026000 D0 NO20026000 D0 NO 20026000D0
Authority
NO
Norway
Prior art keywords
prevention
treatment
heart disease
insulin resistance
disease associated
Prior art date
Application number
NO20026000A
Other languages
English (en)
Other versions
NO20026000L (no
Inventor
Ameet Nathwani
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of NO20026000D0 publication Critical patent/NO20026000D0/no
Publication of NO20026000L publication Critical patent/NO20026000L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20026000A 2000-06-16 2002-12-13 Behandling og forebyggelse av hjertelidelser forbundet med insulinresistens NO20026000L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2000/002347 WO2001095906A1 (en) 2000-06-16 2000-06-16 Treatment and prevention of cardiac insulin resistance associated conditions

Publications (2)

Publication Number Publication Date
NO20026000D0 true NO20026000D0 (no) 2002-12-13
NO20026000L NO20026000L (no) 2003-02-11

Family

ID=9884792

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20026000A NO20026000L (no) 2000-06-16 2002-12-13 Behandling og forebyggelse av hjertelidelser forbundet med insulinresistens

Country Status (15)

Country Link
EP (1) EP1292301A1 (no)
JP (1) JP2004503499A (no)
CN (1) CN1592620A (no)
AP (1) AP2002002688A0 (no)
BG (1) BG107384A (no)
BR (1) BR0017254A (no)
CA (1) CA2436116A1 (no)
DZ (1) DZ3389A1 (no)
EA (1) EA200300028A1 (no)
HU (1) HUP0301103A2 (no)
IL (1) IL153452A0 (no)
MX (1) MXPA02012619A (no)
NO (1) NO20026000L (no)
WO (1) WO2001095906A1 (no)
YU (1) YU1203A (no)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5902726A (en) * 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
WO1998005331A2 (en) * 1996-08-02 1998-02-12 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
WO1999059586A1 (en) * 1998-05-19 1999-11-25 Regents Of The University Of California Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
MA26662A1 (fr) * 1998-07-21 2004-12-20 Smithkline Beecham Plc Derives de thiazolidinedione, compositions pharmaceutiques les contenant et leur utilisation

Also Published As

Publication number Publication date
NO20026000L (no) 2003-02-11
MXPA02012619A (es) 2003-04-10
IL153452A0 (en) 2003-07-06
WO2001095906A1 (en) 2001-12-20
CA2436116A1 (en) 2001-12-20
CN1592620A (zh) 2005-03-09
AP2002002688A0 (en) 2002-12-31
EA200300028A1 (ru) 2003-04-24
YU1203A (sh) 2006-05-25
EP1292301A1 (en) 2003-03-19
HUP0301103A2 (hu) 2003-08-28
DZ3389A1 (fr) 2001-12-20
BR0017254A (pt) 2004-01-06
JP2004503499A (ja) 2004-02-05
BG107384A (bg) 2003-09-30

Similar Documents

Publication Publication Date Title
AU2003290548A8 (en) Prevention and treatment of synucleinopathic disease
IL158469A0 (en) Diagnosis, treatment, and research of mental disorder
HUP0700151A2 (en) Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
AU2002303295B2 (en) Diagnosis and treatment of neural disease and injury using microvoltammetry
HUP0401127A3 (en) Treatment and diagnosis of macrophage disease
NO20034430D0 (no) Tiohydantoiner og anvendelse derav for behandling av diatbetes
NO20014560D0 (no) Quinasoliner og terapautisk anvendelse derav
NO20043370L (no) N-pyrazinylfenylsulfonamider og deres anvendelse ved behandling av kemokinmedierte sykdommer
NO20050569D0 (no) Fremgangsmate for behandling av alvorlig hjertesvikt og medikament for dette
DK1164996T3 (da) Transdermalt terapeutisk system med nikotin og tilsat monoterpenketoner
IS6967A (is) Ný cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
DE50101034D1 (de) Medizinischer oder dentalmedizinischer behandlungsstuhl
ID27576A (id) Penggunaan siklosporin dalam pengobatan penyakit-penyakit peradangan autoimun
HRP20030609A2 (en) Use of il-18 inhibitors for the treatment and/or prevention of heart disease
AU2003233681A8 (en) Diagnosis and treatment of human dormancy syndrome
LU91070B1 (en) Treatment and diagnosis of insulin resistant states
PL371251A1 (en) Carboxamidine derivatives and their use in the treatment of vascular diseases
NO20026000L (no) Behandling og forebyggelse av hjertelidelser forbundet med insulinresistens
AU2003231279A8 (en) Prevention and treatment of type 2 diabetes
EP1322778A4 (en) APPLICATION OF CYR61 IN THE TREATMENT AND DIAGNOSIS OF HUMAN UTERUS MYOMENIC
GB9908059D0 (en) Diagnosis and treatment of diseases
NO20055137D0 (no) Kombinasjon av et makrolid og et lokalbedovelsesmiddel for behandling av hudsykdommer
GB0316940D0 (en) Treatment of skin and other medical conditions
PL360468A1 (en) Treatment and prevention of cardiac insulin resistance associated conditions
MXPA03004074A (es) Derivados de retiferol y su uso en el tratamiento de enfermedades o trastornos de la piel asociadas con fotoda°o.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application